Equillium announces first subject dosed in Phase 1 clinical trial of EQ504

EQ•2026-10-26

Equillium said the first subject has been dosed in its Phase 1 clinical trial of EQ504. The company anticipates topline Phase 1 proof-of-mechanism data in the second quarter of 2027.

1. Trial begins

Equillium announced that the first subject has been dosed in the Phase 1 clinical trial of EQ504. It anticipates topline Phase 1 proof-of-mechanism data in the second quarter of 2027.

Equillium announces first subject dosed in Phase 1 clinical trial of EQ504

1. Trial begins

Related News

Comfort Systems USA: UBS cuts target price to $1,900 from $2,225

Egypt approves military support for Saudi Arabia after Houthi attacks escalate

Nasdaq trade halt continues, with news and resumption times at 09:00 am

RedCloud repays debt in full with shareholder loan

Amazon.com: UBS raises target price to $348 from $318